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Abstract
Background: It is established that Alzheimer’s disease (AD) patients experience sleep
disruption. However, it remains unknown whether disruption in the quantity, quality or
timing of sleep is a risk factor for the onset of AD.
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Methods: We used the largest published genome-wide association studies of self-
reported and accelerometer-measured sleep traits (chronotype, duration, fragmentation,
insomnia, daytime napping and daytime sleepiness), and AD. Mendelian randomization
(MR) was used to estimate the causal effect of self-reported and accelerometer-
measured sleep parameters on AD risk.
Results: Overall, there was little evidence to support a causal effect of sleep traits on AD
risk. There was some suggestive evidence that self-reported daytime napping was asso-
ciated with lower AD risk [odds ratio (OR): 0.70, 95% confidence interval (CI): 0.50–0.99).
Some other sleep traits (accelerometer-measured ‘eveningness’ and sleep duration, and
self-reported daytime sleepiness) had ORs of a similar magnitude to daytime napping,
but were less precisely estimated.
Conclusions: Overall, we found very limited evidence to support a causal effect of sleep
traits on AD risk. Our findings provide tentative evidence that daytime napping may re-
duce AD risk. Given that this is the first MR study of multiple self-report and objective
sleep traits on AD risk, findings should be replicated using independent samples when
such data become available.
Key words: Sleep; Alzheimer’s disease, dementia, Mendelian randomization, causal inference
Introduction
Alzheimer’s disease (AD) has been estimated to affect 47
million people worldwide and the prevalence is expected
to double in the next 20 years.1 Current treatments are un-
able to reverse or delay progression of the disease,
highlighting the importance of prevention. Identifying
causal, modifiable risk factors is crucial for developing suc-
cessful prevention strategies. It is well established that
patients with AD experience sleep disruption (e.g. shorter
duration, greater fragmentation).2 However, it remains un-
known whether disruption in the quantity, quality or tim-
ing of sleep is a causal risk factor for the onset of AD.
Various sleep parameters have previously been sug-
gested as potential risk factors for AD,3–6 but research to
date has yielded inconsistent findings. Authors of the
recent Lancet commission on ‘Dementia prevention, inter-
vention, and care’, did not include sleep in their calcula-
tions of population-attributable fractions of the most
‘potent’ dementia risk factors (despite acknowledging sleep
as a potentially important risk factor) due to the absence of
systematic reviews or enough consistent, high-quality evi-
dence.3 Inconsistencies in the sleep-AD literature may, at
least in part, be explained by bias due to reverse causation.
Most studies have been conducted in clinical populations
(e.g. patients with mild cognitive impairment or early AD),
making it difficult to rule out that associations are not due
to sleep disruption as a result of accumulating AD pathol-
ogy. Very few studies have been conducted in healthy
(non-clinical) populations and, even those that have, tend
to include older participants (i.e. mid- to-late life at base-
line).7 AD has a long prodromal phase of up to 20 years.8
Thus, even in apparently healthy populations, measuring
sleep in later life makes it difficult to rule out that those
participants with sleep disruption are those with prodro-
mal AD. Another potential explanation for the inconsisten-
cies may be the considerable heterogeneity in existing
study designs, which have examined various exposures
(e.g. sleep duration,9 time spent in sleep stages,10 fragmenta-
tion,11 insomnia12 and frequency and duration of daytime
napping13 measured both subjectively and objectively) and
Key Messages
• It is currently not clear whether disrupted sleep is a causal risk factor for Alzheimer’s disease; current observational
associations are likely biased by reverse causation and confounding.
• We employ the largest genome-wide association studies of multiple sleep traits in Mendelian randomization analyses,
to examine whether sleep disruption is causally linked to Alzheimer’s disease risk.
• We find very limited evidence of link between disrupted sleep and risk of Alzheimer’s disease. However, there is ten-
tative evidence that daytime napping may be protective.
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outcomes (e.g. cognitive function at a single time point,14
cognitive decline over time,15 mild cognitive impairment,16
AD diagnoses16 and putative AD biomarkers such as
amyloid-beta and tau13). Finally, the majority of studies
conducted to date are observational, meaning confound-
ing is a plausible explanation for the findings.
Mendelian randomization (MR) is a method that uses ge-
netic variants as instrumental variables for environmental
exposures, to estimate the causal effect of an exposure on an
outcome. Due to their random allocation at conception, ge-
netic markers of a risk factor are largely independent of po-
tential confounders that may otherwise bias the association
of interest. They also cannot be modified by subsequent dis-
ease, thereby eliminating potential bias by reverse causa-
tion.17 Thus, MR is a useful tool for helping to establish
whether sleep traits are causally related to risk of onset of
AD, or whether associations observed to date are likely a re-
sult of bias by confounding and/or reverse causation. In this
study, we aimed to establish whether both self-report and
accelerometer-measured sleep traits have a causal effect on
AD risk, using a two-sample MR design.18
Methods
Methods for conducting two-sample MR analyses have
been published previously.18 Briefly, two-sample MR pro-
vides an estimate of the causal effect of an exposure on an
outcome, using independent samples to obtain the gene-
exposure and gene-outcome associations, provided three
key assumptions hold: (i) genetic variants are robustly as-
sociated with the exposure of interest (i.e. replicate in inde-
pendent samples); (ii) genetic variants are not associated
with potential confounders of the association between the
exposure and the outcome; and (iii) there are no effects
of the genetic variants on the outcome, independent of the
exposure (i.e. no horizontal pleiotropy).19
Data
Genome-wide association studies (GWAS) have been pre-
viously performed for seven self-reported measures of ha-
bitual sleep patterns: chronotype,20 sleep duration,21 long
sleep duration,21 short sleep duration,21 frequent insom-
nia,22 excessive daytime sleepiness23 and daytime napping.
GWAS have also previously been performed for three
accelerometer-measured measures of sleep including timing
of the least active 5 h of the day (L5 timing), nocturnal
sleep duration and sleep fragmentation.24 Note that the as-
sessment of accelerometer-derived sleep for up to 7 days
per individual in UK Biobank was performed, on average,
5 years after the self-report sleep data were collected.25
Full details of each GWAS (e.g. cohorts included, ancestral
groups, exclusion criteria, covariate adjustment etc.)
are provided in Supplementary Table A, available as
Supplementary data at IJE online. Table 1 provides a brief
description of each of the sleep traits, the units in which
they were measured, participant numbers, the number of
approximately independent genome-wide significant (P< 5
x 10-8) loci identified and the F statistic. F statistics provide
an indication of instrument strength26 and are a function
of how much variance in the trait is explained by the set of
genetic instruments being used, the number of genetic
instruments being used and the sample size. F 10 indicates
that the analysis is unlikely to suffer from weak instrument
bias.27 For the outcome, we used the large-scale GWAS
meta-analysis of AD, conducted by the International
Genomics of Alzheimer’s Project (IGAP) (n¼ 17 008 AD
cases and 37 154 controls).28 Ethics approval was obtained
by the original GWAS studies. Figure 1 is a flow chart de-
scribing the data sources for each set of analyses performed.
Statistical analysis
Estimating the causal effects of the sleep traits on
risk of Alzheimer’s disease
Full details of the harmonization procedure can be found in
the online supplement. Supplementary Table B, available as
Supplementary data at IJE online, shows the single nucleo-
tide polymorphism (SNP) flow through the harmonization
procedure. MR-Base (www.mrbase.org)29 was employed to
perform all two-sample MR analyses. Effect estimates and
corresponding standard errors of the genome-wide signifi-
cant SNPs were extracted from each sleep GWAS and the
AD GWAS. The SNP-exposure (sleep trait units detailed in
Table 1 and Figure 2) and SNP-outcome [AD, in units of log
odds ratios (ORs] coefficients were combined using an
inverse-variance-weighted (IVW) approach to give an over-
all estimate of the causal effect across all SNPs included for
each sleep trait. The estimator is a Wald ratio and is equiva-
lent to a weighted regression of the SNP-outcome coeffi-
cients on the SNP-exposure coefficients with the intercept
constrained to zero. The results of all analyses were con-
verted to ORs for AD. For binary exposures (i.e. frequent
insomnia, and long and short sleep duration), SNP-exposure
coefficients were estimated using logistic regression and are
therefore on the log odds scale. Causal effect estimates (i.e.
ORs for AD) have been rescaled so that they are interpreted
per doubling of genetic liability for the sleep trait, as recom-
mended by Burgess et al.30 For ordered categorical expo-
sures, SNP-exposure coefficients were estimated using linear
regression, and causal effect estimates are interpreted per
category increase in the sleep trait. For continuous expo-
sures, SNP-exposure coefficients were estimated using linear
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regression, and causal effect estimates are interpreted per
unit increase in the sleep trait (units detailed in Table 1 and
Figure 2).
Sensitivity analyses
A series of sensitivity analyses were conducted to check for
violation of the key MR assumptions. The rationale and
methodological details for each of these analyses are pro-
vided in the online supplement. The IVW method assumes
no horizontal pleiotropy but will be unbiased if there is
balanced horizontal pleiotropy.19 Thus, results from the
IVW method were compared with those from MR-Egger19
and weighted median regressions31 which relax this as-
sumption. The IVW method also assumes no measurement
error in the gene-exposure association estimates (i.e. the
Table 1 Description of the sleep genome-wide association studies (GWAS) included in the two-sample Mendelian randomiza-
tion analyses






Chronotype20 Whether a person identifies as being a
‘morning person’ or an ‘evening person’
(ordered categorical variable of definitely
a morning person, more a morning than
an evening person, do not know, more an
evening than morning person and defi-
nitely an evening person)a
449 734 351 33.1
Sleep duration21 Average number of hours slept in 24 h, in-
cluding naps (continuous variable, hours)
446 118 78 39.6
Short sleep duration21 Person has an average of 6 h or less per
night vs 7-8 h per 24 h (binary variable
of yes/no)
411 934 (106 192/305 742) 27 25.6
Long sleep duration21 Person has an average of 9 h or more per
night vs 7-8 h per 24 h (binary variable
of yes/no)
339 926 (34 184/305 742) 8 30.6
Frequent insomnia22 Person has trouble falling asleep at night or
wakes up in the middle of the night (bi-
nary variable of usually vs never/rarely)
453 379 (131 480/321 899) 48 41.7
Excessive daytime
sleepiness23
Person dozes off or falls asleep during the
day without meaning to (ordered cate-
gorical variable of never or rarely, some-
times, often and all the time)
452 071 37 42.3
Daytime napping Person naps during the day (ordered cate-
gorical variable of never, sometimes,
usually)
452 633 112 46.1
Accelerometer measures
L5 timing24 Timing of the least active 5 h of the day
(continuous variable of hours elapsed
since previous midnight; provides indica-
tion of phase of most restful hours with
later times indexing greater tendency to-
wards ‘eveningness’)
85 205 6 55.3
Sleep duration24 Average number of hours of nocturnal sleep
per night (continuous variable, hours)
84 810 11 52.1
Sleep fragmentation24 The average number of nocturnal sleep epi-
sodes separated by at least 5 min of
wakefulness per night (continuous vari-
able, number of episodes)
84 810 21 38.6
aNote that in the original chronotype GWAS, categories were ordered from more ‘eveningness’ to more ‘morningness’. In this analysis, to ensure that the ordi-
nal chronotype variable correlated positively with the accelerometer-measured measure of L5 timing, single nucleotide polymorphism (SNP)-exposure coefficients
for chronotype were reordered from more ‘morningness’ to more ‘eveningness’ (where ‘definitely a morning person’ is the reference category).
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NOME assumption).19 We assessed this using an adapta-
tion of the I2 statistic32 (referred to as I2GX) which provides
an estimate of the degree of regression dilution in the MR-
Egger causal estimate due to uncertainty in the SNP-
exposure estimates. Simulation extrapolation (SIMEX)
was then used to adjust the MR-Egger estimate for this di-
lution.33 Heterogeneity (i.e. variability in causal estimates
from different genetic variants) was assessed using
Cochran’s Q statistic.19 Funnel plots were then generated
to enable visual assessment of the extent to which
Figure 2 Associations of sleep traits with Alzheimer’s Disease. Note that the MR Egger estimate for the effect of daytime sleepiness was not plotted
due to imprecision. IVW, Inverse Variance Weighted
Figure 1 Flow chart detailing data sources for each analysis performed. AD, Alzheimer’s disease; GWAS, genome-wide association study; MR,
Mendelian randomization; IGAP, International Genomics of Alzheimer’s Project; IVW, Inverse Variance Weighted; PGC, Psychiatric Genomics
Consortium; ADSP, Alzheimer’s Disease Sequencing Project
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pleiotropy is likely to be balanced (or directional) across
the set of instruments used in each analysis. Radial MR
was used to detect and remove any SNP outliers (i.e. those
SNPs that contribute the most heterogeneity to Cochran’s
Q, based on a multiple testing corrected P-value thresh-
old). Leave-one-out permutations were conducted to assess
the undue influence of potentially pleiotropic SNPs on the
causal estimates.34 We checked that results were similar af-
ter excluding palindromic SNPs.35 Steiger filtering was per-
formed to test that the hypothesized causal direction was
correct for each SNP (i.e. that the genetic instruments in-
fluence the exposure first and then the outcome, through
the exposure).36 Finally, we investigated potential bias due
to ‘winner’s curse’ where the magnitude of the effect sizes
for variants identified within a single discovery sample are
likely to be larger than in the overall population, even if
they are truly associated with the exposure. Assessment of
winner’s curse was only possible for frequent insomnia and
sleep duration, where the GWAS were replicated in inde-
pendent samples [the Nord-Trøndelag Health Study
(HUNT) and the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE), respectively]. Details
of the replication samples and winners curse analyses are
in the online supplement.
Additional analyses
To examine whether the previously observed associations
between AD (as an exposure) and sleep disruption (as an
outcome)2 could be supported through applying MR ana-
lytical approaches, we tested whether genetic liability for
AD was causally associated with the self-reported and
accelerometer-measured sleep traits. We used 20 indepen-
dent genome-wide significant AD SNPs identified in the
IGAP AD GWAS meta-analysis (described previously)28 as
genetic instruments in these analyses. As with the main
analysis of sleep traits on AD risk, SNP-exposure and SNP-
outcome coefficients were combined using an inverse-
variance-weighted (IVW). MR-Egger, weighted median,
radial MR and Steiger filtering were performed to assess
potential violation of the MR assumptions. Analyses were
conducted both with and without the apolipoprotein E
(APOE) variant included, as APOE has been previously
shown to be pleiotropic37 (which violates an MR assump-
tion). We also examined associations of APOE (as a single
genetic instrument) with the sleep traits. As AD is a binary
exposure and SNP-exposure coefficients are on the log
odds scale, causal estimates for the effect of AD on sleep
traits are rescaled so that they are interpreted per doubling
of genetic liability for AD.
It is worth noting that there are several important limi-
tations to these analyses. First, the average age of AD
diagnosis in the UK is around 75 years,38 with the neuro-
psychological effects of prodromal disease detectable up to
8 years preceding a diagnosis of mild cognitive impairment
(i.e. around 10–12 years before AD diagnosis).39 Thus, the
majority of UK Biobank participants are likely too young
(average age at recruitment 56 years40) to have even pro-
dromal disease at the time the sleep traits were measured.
Examining the effect of AD on sleep traits in a relatively
young, healthy population (when we hypothesize that any
effects of AD on sleep traits will likely be a result of in-
creasing pathological burden) may not yield reliable
results. Second, there is ‘healthy selection’ into the UK
Biobank; only approximately 5% of those invited to par-
ticipate in the study accepted the invitation,41 and there is
evidence that genetic liability to AD is associated with
lower participation rates in the optional components of
UK Biobank.42 This makes it less likely that participants
with an existing AD diagnosis or undiagnosed prodromal
disease would have been recruited into the study, and
again, may induce bias in the causal effect estimates.
Post hoc analyses
After the completion of the analyses for this paper, an
updated AD GWAS meta-analysis was published43 includ-
ing the aforementioned IGAP, the AD working group of
the Psychiatric Genomics Consortium and the AD
Sequencing Project (Phase 1; n¼ 24 087 cases and 55 058
controls compared with n¼ 17 008 AD cases and 37 154
controls for IGAP alone). We therefore conducted a sensi-
tivity analysis to assess whether causal effects were consis-
tent when using the newer GWAS. We a priori decided not
to use summary statistics from the Phase 3 meta-analysis
(which includes UK Biobank), but instead use the Phase 1
(which excludes UK Biobank) for two reasons: first, all
sleep trait GWASs include the UK Biobank, meaning there
would be significant overlap between the exposure and
outcome samples in each MR analysis. This can yield bi-
ased causal effect estimates.44 Second, the Phase 3 AD
GWAS meta-analysis includes only AD-by-proxy cases
from the UK Biobank (i.e. no diagnosed cases). AD-by-
proxy cases were defined as a positive response to the ques-
tion ‘Has your mother or father ever suffered from
Alzheimer’s disease/dementia’. There are several potential
problems with this for MR analyses: participants defined
as cases have not themselves been diagnosed with AD; the
question does not specify Alzheimer’s disease but asks
about any form of dementia; and finally, the question does
not ask if family members were diagnosed by a doctor. For
ease of the reader, we will henceforth refer to the main
IGAP analyses as being in the ‘IGAP-only data’, and the
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additional analyses with the newer published GWAS as be-
ing in the ‘META data’.
Results
Main analyses in ‘IGAP-only data
Supplementary Table C, available as Supplementary data at
IJE online, shows the phenotypic correlations between each
of the sleep traits. Correlations between accelerometer
measures have been published previously.24 Correlations
were generally weak, ranging from r ¼ -0.001 (between
accelerometer-measured L5 timing and accelerometer-
measured sleep duration) to r ¼ -0.32 (between self-report
frequent insomnia and self-report short sleep duration). It is
also worth noting that correlations were weak between self-
reported and accelerometer-measured sleep duration
(r¼ 0.15). This may reflect that accelerometer data in the
UK biobank were collected between 2 and 9 years (mean
5 years)24 after baseline, when self-reported sleep measures
were assessed. It may also reflect that self-reports of global
sleep duration (vs daily self-reported) can be influenced by
distress/affect.45
Figure 2 shows results for the analysis of the sleep traits
on risk of AD. Full results can be found in Supplementary
Table D, available as Supplementary data at IJE online.
Point estimates for self-reported chronotype, insomnia and
sleep duration were very close to or on the null. Both
shorter and longer self-reported sleep duration and
accelerometer-measured sleep fragmentation yielded posi-
tive estimates with AD risk, but were imprecisely esti-
mated. There was some tentative evidence of a protective
effect of self-reported daytime napping on AD risk, with
odds of AD being 33% lower (95% CI: 55% lower to 2%
higher) per category increase from ‘never’, ‘sometimes’ to
‘usually’ napping. However, this was again imprecisely es-
timated. Odds ratios for greater accelerometer-measured
‘eveningness’, longer accelerometer-measured sleep dura-
tion and self-reported daytime sleepiness were similar in
magnitude to daytime napping, although again with wide
confidence intervals.
Sensitivity analyses in IGAP-only data
For all analyses, there was little evidence of directional
pleiotropy from the MR-Egger regression intercepts
(Supplementary Table E, available as Supplementary data
at IJE online), and causal effect estimates from the MR-
Egger and weighted median regressions generally agreed
with those from the IVW regressions; in all cases there was
substantial overlap between the confidence intervals for
each estimate (Supplementary Table D, available as
Supplementary data at IJE online). As expected, precision
was less for MR-Egger (due to estimating both an intercept
and slope in the MR-Egger regression as opposed to only a
slope in the IVW regression) and weighted median (due to
assuming only 50% of the instruments are valid). I2GX sta-
tistics are provided in Supplementary Table F, available as
Supplementary data at IJE online and SIMEX-adjusted
MR-Egger estimates in Supplementary Table D. These esti-
mates were consistent with regression dilution of the MR-
Egger causal effect estimates due to measurement error in
the SNP-exposure estimates. There was evidence of
between-SNP heterogeneity in the self-reported chronotype
and daytime napping, and accelerometer-measured L5-tim-
ing analyses (Supplementary Table G, available as
Supplementary data at IJE online). However, these were not
unduly asymmetrical in the funnel plots (Supplementary
Figures A–C, available as Supplementary data at IJE on-
line), suggesting that directional pleiotropy is unlikely to
bias the effect estimates for these sleep traits. A total of three
outliers were detected by radial MR for sleep fragmentation
(rs12714404, rs429358 and rs4974697) and one for L5 tim-
ing (rs1144566). Point estimates for these two traits attenu-
ated towards the null after removal of these outliers
(Supplementary Table H, available as Supplementary data
at IJE online). Results were similar after removing each SNP
in turn in the leave-one-out permutations (Supplementary
Figures D–M, available as Supplementary data at IJE on-
line), suggesting that no single SNP was having undue influ-
ence on the overall causal effect estimates. Results were also
similar when palindromic SNPs were excluded from the
analyses (Supplementary Table I, available as
Supplementary data at IJE online). Steiger filtering provided
evidence that for each MR analysis, SNPs explained more
variation in the sleep trait than in AD. Findings for the sleep
duration and insomnia results were similar when repeating
analyses using the available replication datasets (i.e. using
SNP-exposure estimates from independent datasets)
(Supplementary Table J, available as Supplementary data at
IJE online), providing evidence that bias due to winner’s
curse is unlikely.
Additional analyses in IGAP-only data
Associations between genetic liability for AD and all sleep
traits are provided in Supplementary Table K, available as
Supplementary data at IJE online. All point estimates are
interpreted per doubling of genetic risk for AD. There was
little evidence that genetic liability for AD was associated
with short sleep duration (<6 h vs 7–8 h per 24 h) or day-
time sleepiness. Increased genetic liability for AD was asso-
ciated with less frequent insomnia, reduced daytime
napping and reduced sleep fragmentation. The effects were
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very small in magnitude (e.g. a doubling of genetic liability
for AD was associated with, on average, a 0.4% lower risk
of frequent insomnia). Point estimates for associations of
genetic liability for AD with all other sleep traits were also
very close to or on the null (e.g. a doubling of genetic lia-
bility for AD was associated with, on average, 0.3 min
lower sleep duration). P-values were small, likely due to
the strength of APOE as an instrument for AD. This is sup-
ported by the fact that, when using the full set of AD ge-
netic instruments minus APOE, point estimates remained
largely unchanged but confidence intervals were wider
(Supplementary Table L, available as Supplementary data
at IJE online). Given that these causal effect estimates are
per doubling of genetic liability for AD, the magnitude of
effect is very small and not likely to be clinically important.
Results were similar when using APOE alone as an instru-
ment for AD (i.e. excluding all other AD SNPs,
Supplementary Table M, available as Supplementary data
at IJE online). Results were comparable when using MR-
Egger and weighted median regressions (Supplementary
Table K) and after removal of outliers detected by radial
MR (Supplementary Table N, available as Supplementary
data at IJE online). Steiger filtering provided evidence that
for each MR analysis, all AD SNPs explained more varia-
tion in AD than in the sleep trait. Given our concerns
about selection bias in the UK Biobank for these analy-
ses,46 we performed a post hoc analysis to assess whether
causal effect estimates were comparable when using a dif-
ferent outcome sample. Methods for these analyses are
provided in the online supplement. We tested the associa-
tion between genetic liability for AD and frequent insom-
nia in n¼62 533 participants from the Nord-Trøndelag
Health Study (HUNT).47 HUNT is a less selected sample
with over 60% response rate (compared with <5% for UK
Biobank). Results were comparable to the main analyses
using UK Biobank, except that confidence intervals were
wider (IVW odds ratio: 0.98 per doubling of genetic
liability for AD, 95% CI: 0.95 to 1.01 in HUNT, vs IVW
odds ratio: 0.99 per doubling of genetic liability for AD,
95% CI: 0.99 to 1.00 in the UK Biobank, Supplementary
Table O, available as Supplementary data at IJE online).
Post hoc analysis in the ‘META data’
Causal effect estimates for associations of sleep traits on
risk of AD were very similar when using the largest meta-
analysis GWAS for AD, typically with more precision
around the causal estimates (Figure 3). There was consis-
tent evidence of a protective effect of daytime napping on
Alzheimer’s risk, with odds of AD being 36% lower (95%
CI: 11% to 45%) per category increase from ‘never’,
‘sometimes’ to ‘usually’ napping in the IVW analysis.
Effects were consistent across several pleiotropy-robust
methods, including MR Egger and weighted median
approaches.
Discussion
We have used the largest genome-wide association studies
available of self-report and accelerometer-measured sleep
traits and diagnosed Alzheimer’s disease, to provide evi-
dence on possible causal relationships between them.
Overall, based on both the IGAP-only data and the META
data presented in this study, we found very little evidence
to support a causal link between these sleep traits and risk
of AD, except for some suggestive evidence that daytime
napping may be associated with lower risk of AD. It is
worth noting that odds ratios for accelerometer-measured
‘eveningness’, accelerometer-measured sleep duration and
self-reported daytime sleepiness were similar in magnitude
to daytime napping, but that confidence intervals were too
wide to draw any meaningful conclusions (indicating that
power is likely a key limitation here).
Figure 3 Comparing results for associations of sleep traits on risk of Alzheimer’s disease (AD) when using the International Genomics of Alzheimer’s
Project (IGAP) genome-wide association study (GWAS) alone (n¼ 17 008 AD cases and 37 154 controls; IGAP) vs the GWAS meta-analysis of IGAP,
the AD working group of the Psychiatric Genomics Consortium and the AD Sequencing Project (n¼ 24 087 cases and 55 058 controls: META data).
Note that the MR Egger estimate for effect of accelerometer-measured sleep fragmentation using IGAP data was not plotted due to imprecision. MR,
Mendelian randomization; AM, accelerometer-measured; SR, self-report
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We found increased genetic liability for AD was associ-
ated with less frequent insomnia, reduced daytime napping
and reduced sleep fragmentation. However, it is important
to note that point estimates were very close to the null, and
given that they are per doubling of genetic liability for AD,
are unlikely to be clinically important. Confidence inter-
vals around these point estimates were likely narrow due
to the inclusion of APOE as a genetic instrument for AD
(as it is strongly and robustly associated with a 3- to 15-
fold increase in AD risk43); confidence intervals were much
wider when we excluded this instrument. Although these
associations are in the opposite direction to what we
expected, these results should be treated with caution be-
cause of the potential for selection bias within the UK
Biobank (which can cause spurious associations46) where
participants are relatively young and healthier than the
general population. In light of this and based on our largely
null results, we would not rule out reverse causation as a
potential explanation for previous findings in observa-
tional studies.
We looked only at frequency (not duration) of daytime
napping, as information on duration of naps is not cur-
rently available in the UK Biobank. Previous studies have
reported both positive and negative outcomes observed in
relation to napping, and there is evidence that the duration
may be particularly important (with shorter naps being
beneficial, and longer naps being detrimental for various
health outcomes including cardiovascular risk, cognitive
impairment and memory consolidation).48,49 Most studies
to date linking daytime napping to poor health outcomes
have been done in elderly populations,50,51 making it diffi-
cult to rule out that (in those studies) daytime napping is
not merely a result of underlying disease, rather than being
a cause of the poor outcomes. In addition, it is often not
possible in those studies to separate whether it is poor noc-
turnal sleep or the consequential daytime napping that is
associated with the adverse outcomes. Conversely, there is
some evidence that daytime naps offer a variety of benefits
including memory consolidation52 and improvements in
subsequent learning,53 executive functioning and emo-
tional processing,54 all of which are impaired in AD.55
There is also evidence that short, restorative naps
(<60 min in duration) may reduce the rate of cardiovascu-
lar disease and low-grade inflammation.49 Thus, daytime
napping (before the onset of preclinical disease) may po-
tentially serve as a useful compensatory mechanism for
poor nocturnal sleep, enabling the brain to carry out tasks
it was unable to complete during the night (for example,
due to fragmented or short sleep).
There have been three twin-studies examining the rela-
tionship between sleep disruption and dementia risk,
which may help mitigate bias due to confounding.56–58
However, two studies acknowledge that they are under-
powered and include the null value,56,57 making it difficult
to draw any inferences about causality, and one study in-
cluded participants over age 65 years (with most being
over age 70 years), making it plausible that estimates are
biased by reverse causation.58 A recent MR study exam-
ined the causal effects of sleep duration on various demen-
tia and cognitive function outcomes. Using standard MR
methods, greater sleep duration was associated with slower
reaction times and more errors in visual memory (with
both outcomes measured as continuous variables), but
there was no robust evidence of causal effects on reaction
time or visual memory (both binary variables derived from
the standardized regression-based method), all-cause de-
mentia or, similar to our study, Alzheimer’s disease.
Observing no associations with any of the binary outcomes
may be due to a lack of power, as in our study. The authors
also explored possible non-linearity in a one-sample frame-
work, by generating three subgroups based on the residuals
of sleep duration after adjustment on genetic instruments.
This method explores the linear effect of sleep duration
within each of these subgroups, and tests for evidence of a
difference in associations (interactions) across them. They
found evidence that associations with poorer visual mem-
ory and reaction time were stronger for both the lower and
the higher duration subgroup than the middle one.
However, it is worth noting that this method is limited for
assessing non-linearity (as it is only really possible to ob-
tain three strata) and may induce collider bias in cases
where data are not measured continuously (as with self-
report sleep duration in UK Biobank, which is measured
categorically).59
Strengths and limitations
To our knowledge, this is the first study to examine the
causal effect of various sleep traits on risk of AD, using
MR. We have both self-reported and accelerometer-
assessed measures of sleep, allowing a comprehensive eval-
uation of various sleep parameters and a comparison
across the two methods of assessment. We conducted a
comprehensive series of sensitivity analyses to examine
whether our results were robust to the various assumptions
of MR or were likely to be biased by horizontal pleiotropy.
We were also able to replicate some of our findings using
independent exposure datasets (i.e. for self-report sleep du-
ration and insomnia), and results were consistent, suggest-
ing our findings are unlikely to be biased by winner’s
curse. Findings were also largely consistent when we per-
formed MR using summary statistics from a more recent
GWAS meta-analysis of Alzheimer’s disease.43
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There are, however, several limitations to our study.
The first limitation is statistical power; confidence intervals
were wide for most sleep traits (despite using the largest
available GWASs), limiting our ability to draw meaningful
conclusions for many associations. Identifying stronger
instruments for these sleep traits may increase statistical
power and enable us to estimate their causal effects on AD
risk more precisely. The second limitation is that some
SNPs may overlap across sleep traits. It would be of inter-
est to perform multivariable MR analysis to fully delineate
the independent effects of each of the sleep traits, but we
would be underpowered to draw inferences from this with
seven traits, some of which have very few genetic markers.
This should, however, have little consequence for the inter-
pretation of our results. Concern here would be about hor-
izontal pleiotropy (an observed causal effect on the
outcome that does not go via the exposure of interest, but
another trait). Pleiotropy is important to consider in the
context of non-null results, as we want to have some cer-
tainty that the pathway from gene to outcome goes via the
exposure of interest. Our results are largely null, meaning
there is little evidence of a direct effect of the exposure, or
a pleiotropic effect, on the outcome. It is plausible that
pleiotropy could act in the opposite direction to the true
causal effect and bias estimates towards the null. However,
this is unlikely given: (i) that none of the extensive sensitiv-
ity analyses performed suggest that pleiotropy is biasing ef-
fect estimates; and (ii) we observe no causal effects for any
other (pleiotropic) sleep traits. Thus, pleiotropy is an un-
likely explanation for our findings. The third limitation is
that, for some sleep traits (e.g. self-report long-sleep dura-
tion and for accelerometer L5 timing and sleep duration),
there were very few genome-wide significant SNPs identi-
fied in their respective GWASs (and thus available for use
in our MR analyses). This made it difficult to examine po-
tential directional horizontal pleiotropy using funnel plots
for these traits. However, given that there was only evi-
dence of heterogeneity for L5 timing, daytime napping and
chronotype (and the chronotype and daytime napping
showed no marked asymmetry in the funnel plot), horizon-
tal pleiotropy is unlikely to explain our findings. Third, we
did not correct for multiple testing because several of the
sleep traits are correlated, but the results need to be inter-
preted in this light, and replication of our findings is re-
quired. Fourth, it is possible that the specific features of
sleep that are implicated in the pathogenesis of AD (for ex-
ample, disruption of slow-wave sleep) are not detectable
using accelerometers or subjectively. Fifth, there may be a
threshold effect of daytime napping by which shorter naps
are beneficial and long, frequent naps may be detrimental.
Previous studies have suggested this may be the case (par-
ticularly for cardiovascular risk, cognitive impairment and
memory consolidation49) but we are unable to unpick
these effects with current data in an MR framework. Sixth,
most analyses were conducted using data from the UK
Biobank, which may not be representative of the general
population (due to selection into the study).41 That said,
results were similar when using data from independent rep-
lication samples (including HUNT and CHARGE). All
GWAS samples were also restricted to participants of
European ancestry and therefore may not be generalizable
to other populations. Finally, no sleep diaries were col-
lected in the UK Biobank to identify time in bed and out of
bed, which may introduce measurement error into some of
the accelerometer measures. However, for the sleep data
used in this study, times in and out of bed were estimated
using a validated algorithm to determine the sleep period
time window.60
Conclusions
We found very limited evidence to support disrupted sleep
as a causal risk factor for AD. Our results tentatively sug-
gest that daytime napping may reduce AD risk. Given that
this is the first MR study of multiple self-report and objec-
tive sleep traits on AD risk, findings should be replicated
using independent samples when such data become avail-
able. Identifying stronger instruments for all sleep traits
will be useful in more precisely estimating any causal
effects on AD risk.
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